Reuters - Health Report

Click to View in Browser

Tuesday, November 7, 2017

Insurers step up pitch for Obamacare as government slashes its effort

NEW YORK (Reuters) - President Donald Trump's 90 percent cut to Obamacare advertising has U.S. health insurers in many states digging deeper into their pockets to get the word out about 2018 enrollment, which opened last week.

Kentucky accuses Endo of contributing to opioid epidemic

(Reuters) - Kentucky accused units of Endo International Plc on Monday of contributing to drug overdoses and an opioid epidemic by deceptively marketing its painkiller Opana ER, the latest lawsuit by state or local governments against the drugmaker.

China's Creat suffers setback in Biotest deal on U.S. scrutiny

FRANKFURT (Reuters) - Chinese investor Creat Group Corp has withdrawn its application for U.S. approval of a planned 1.3-billion-euro ($1.51-billion) takeover of Biotest , the German blood plasma products maker said, sending its shares sharply lower.

FDA approves Roche drugs for rare types of blood, lung cancers

(Reuters) - Roche Holding AG won U.S. approval to market its skin cancer drug Zelboraf for certain patients with Erdheim-Chester Disease, a rare type of blood cancer, and to market its drug Alecensa as a first choice of treatment for a subset of patients with non-small cell lung cancer.

Brexit with no deal risks chaos in drug supply, report warns

LONDON (Reuters) - Crashing out of the European Union without a deal would cause major problems for Britain's health service and risk "chaotic disruption" to medicine supplies, according to a report on Tuesday.

Takeda takes on Sanofi with new global dengue vaccine data

(Reuters) - Takeda Pharmaceutical's experimental dengue vaccine has produced promising long-term results in clinical tests, boosting the Japanese company's global hopes for a product that will take on Sanofi's Dengvaxia.

New Delhi pollution hits dangerous level, putting runners at risk

NEW DELHI (Reuters) - Pollution in the Indian capital on Tuesday hit a dangerous level at which everyone is at risk and doctors called for the city's half marathon this month to be canceled.

Valeant to sell female libido pill business back to former owners

(Reuters) - Valeant Pharmaceuticals International Inc said on Monday it will sell its female libido-pill business Sprout Pharmaceuticals back to its former owners, two years after buying the company for about $1 billion.

Bayer in bid to broaden use of anti-clotting drug Xarelto

FRANKFURT (Reuters) - German drugmaker Bayer on Monday moved to tap a potentially lucrative new market opportunity for its blockbuster clot prevention drug Xarelto, requesting approval in Europe to make atherosclerosis patients eligible for treatment.

Leading cause of impaired vision in U.S. is correctable

(Reuters Health) - Many people in the U.S. have vision problems that could be addressed with glasses, contact lenses or eye surgery, a recent study suggests.